These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24507816)

  • 21. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
    Jädersten M; Montgomery SM; Dybedal I; Porwit-MacDonald A; Hellström-Lindberg E
    Blood; 2005 Aug; 106(3):803-11. PubMed ID: 15840690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
    Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
    Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
    [No Abstract]   [Full Text] [Related]  

  • 23. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
    Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
    Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
    Hellström-Lindberg E
    Hematology Am Soc Hematol Educ Program; 2005; ():161-6. PubMed ID: 16304375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes.
    Della Porta MG
    Leuk Res; 2011 Jan; 35(1):22-3. PubMed ID: 20727588
    [No Abstract]   [Full Text] [Related]  

  • 30. Myelodysplastic syndrome.
    Hofmann WK; Koeffler HP
    Annu Rev Med; 2005; 56():1-16. PubMed ID: 15660498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
    Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
    Sekeres MA; Schoonen WM; Kantarjian H; List A; Fryzek J; Paquette R; Maciejewski JP
    J Natl Cancer Inst; 2008 Nov; 100(21):1542-51. PubMed ID: 18957672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
    Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
    Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins.
    Santini V
    Semin Hematol; 2012 Oct; 49(4):295-303. PubMed ID: 23079059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
    Bowen D; Hyslop A; Keenan N; Groves M; Culligan D; Johnson P; Shaw A; Geddes F; Evans P; Porter J; Cavill I
    Haematologica; 2006 May; 91(5):709-10. PubMed ID: 16670077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.
    Tehranchi R
    Med Oncol; 2006; 23(1):37-49. PubMed ID: 16645228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing patients with low-risk MDS.
    Sekeres M; Cosgrove D; Falco A
    Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.